Bilateral Subcapsular Cataract in A Patient with Crohn's Disease Taking Oral Budesonide Therapy: A Case Report: Budesonide and Cataract

Atilla Bulur; Kamil Özdil; Nermin Mutlu Bilgiç; Kemal Kürbüz; Oğuzhan Öztürk; Zuhal Çalışkan; Süleyman Sayar; Roni Atalay; Hamdi Levent Doğanay

doi:10.5281/zenodo.10019776

Authors

Atilla Bulur Private Gastroenterology and Endoscopy Clinic, Nazilli, Aydin, Turkey https://orcid.org/0000-0001-8089-7740
Kamil Özdil Umraniye Traning and Research Hospital, Department of Gastroenterology, Istanbul, Turkey https://orcid.org/0000-0003-2556-3064
Nermin Mutlu Bilgiç Umraniye Traning and Research Hospital, Department of Gastroenterology, Istanbul, Turkey https://orcid.org/0000-0003-0486-1767
Kemal Kürbüz Pendik Medical Park Hospital, Department of Gastroenterology, Istanbul, Turkey https://orcid.org/0000-0001-9602-0644
Oğuzhan Öztürk Umraniye Traning and Research Hospital, Department of Gastroenterology, Istanbul, Turkey https://orcid.org/0000-0002-7718-8684
Zuhal Çalışkan Umraniye Traning and Research Hospital, Department of Gastroenterology, Istanbul, Turkey
Süleyman Sayar Umraniye Traning and Research Hospital, Department of Gastroenterology, Istanbul, Turkey https://orcid.org/0000-0001-7089-6082
Roni Atalay Ankara City Hospital, Department of Gastroenterology, Ankara, Turkey https://orcid.org/0000-0002-3781-5110
Hamdi Levent Doğanay Pendik Medical Park Hospital, Department of Gastroenterology, Istanbul, Turkey https://orcid.org/0000-0002-2263-6689

DOI:

https://doi.org/10.5281/zenodo.10019776

Keywords:

Budesonide, Crohn's disease, cataract

Abstract

Crohn's disease is a chronic, inflammatory disease of the gastrointestinal tract, which can progress with remission and flares. In order to maintain remission, initially; systemic glucocorticoids such as prednisolone are used. However, since these traditional glucocorticoids have too many side effects, second-generation drugs such as budesonide, which has much fewer systemic side effects, are now used. However, in the case we presented, a bilateral posterior subcapsular cataract developed in a Crohn's patient followed up with oral budesonide therapy. It was seen that there was no such case report in the literature.

References

Lichtenstein GR, Bengtsson B, Hapten-White L, Rutgeerts P. Oral budesonide for maintenance of remission of Crohn's disease: a pooled safety analysis. Aliment Pharmacol Ther. 2009;29(6):643-653. doi:10.1111/j.1365-2036.2008.03891.x

Yang YX, Lichtenstein GR. Corticosteroids in Crohn's disease. Am J Gastroenterol. 2002;97(4):803-823. doi:10.1111/j.1572-0241.2002.05596.x

Miehlke S, Acosta MB, Bouma G, et al. Oral budesonide in gastrointestinal and liver disease: A practical guide for the clinician [published online ahead of print, 2018 Mar 30]. J Gastroenterol Hepatol. 2018;10.1111/jgh.14151. doi:10.1111/jgh.14151

Kumar A, Cole A, Segal J, Smith P, Limdi JK. A review of the therapeutic management of Crohn's disease. Therap Adv Gastroenterol. 2022;15:17562848221078456. Published 2022 Feb 17. doi:10.1177/17562848221078456

Rutgeerts P, Löfberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med. 1994;331(13):842-845. doi:10.1056/NEJM199409293311304

Moja L, Danese S, Fiorino G, Del Giovane C, Bonovas S. Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease. Aliment Pharmacol Ther. 2015;41(11):1055-1065. doi:10.1111/apt.13190

Delbarre M, Froussart-Maille F. Sémiologie et formes cliniques de la cataracte chez l’adulte [Signs, symptoms, and clinical forms of cataract in adults]. J Fr Ophtalmol. 2020;43(7):653-659. doi:10.1016/j.jfo.2019.11.009.

Yan H, Tan X, Yu J, et al. The occurrence timeline of steroid-induced ocular hypertension and cataract in children with systemic autoimmune diseases. Int Ophthalmol. 2022;42(7):2175-2184. doi:10.1007/s10792-022-02217-5

Kačmař J, Cholevík D. Corticosteroid Induced Posterior Subcapsular Cataract. KORTIKOSTEROIDY INDUKOVANÁ ZADNÍ SUBKAPSULÁRNÍ KATARAKTA. Cesk Slov Oftalmol. 2019;74(6):226-232. doi:10.31348/2018/6/2

Abuekteish F, Kirkpatrick JN, Russell G. Posterior subcapsular cataract and inhaled corticosteroid therapy. Thorax. 1995;50(6):674-676. doi:10.1136/thx.50.6.674

Simons FE, Persaud MP, Gillespie CA, Cheang M, Shuckett EP. Absence of posterior subcapsular cataracts in young patients treated with inhaled glucocorticoids. Lancet. 1993;342(8874):776-778. doi:10.1016/0140-6736(93)91541-s

Schlenker MB, Thiruchelvam D, Redelmeier DA. Association of Cataract Surgery With Traffic Crashes. JAMA Ophthalmol. 2018;136(9):998-1007. doi:10.1001/jamaophthalmol.2018.2510

Good WV. Cataract surgery in young children. Br J Ophthalmol. 2001;85(3):254. doi:10.1136/bjo.85.3.254

Crawford JS. Conservative management of cataracts. Int Ophthalmol Clin. 1977;17(4):31-35.

Gomollón F, Dignass A, Annese V, et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis. 2017;11(1):3-25. doi:10.1093/ecco-jcc/jjw168

Campieri M, Ferguson A, Doe W, Persson T, Nilsson LG. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut. 1997;41(2):209-214. doi:10.1136/gut.41.2.209

Bilateral Subcapsular Cataract in A Patient with Crohn's Disease Taking Oral Budesonide Therapy: A Case Report

Budesonide and Cataract

Authors

DOI:

Keywords:

Abstract

References

Downloads

Published

How to Cite

Issue

Section

Categories

License

Most read articles by the same author(s)

Publisher

Make a Submission

Information

Announcements

Translation

Book Projects

INDEXING AND ABSTRACTING